TrialBlood advances2026

Tildrakizumab for the prophylaxis of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.

Lyndsey Runaas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.